ALLSCHWIL, SWITZERLAND – 4 July 2006 – A study published in Circulation showed that patients with Eisenmenger’s syndrome, a severe form of pulmonary arterial hypertension (PAH) developed as a complication of a congenital heart defect, responded positively to treatment with bosentan (Tracleer®).1 Eisenmenger’s syndrome is the most advanced form of PAH related to congenital heart disease, exercise capacity is particularly poor even in comparison to other forms of Congenital Heart Disease (CHD) and is associated with organ damage and a higher likelihood of premature death.2
